Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 2
2014 5
2015 1
2016 4
2017 1
2018 8
2019 4
2020 5
2021 7
2022 6
2023 7
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

48 results

Results by year

Filters applied: . Clear all
Page 1
Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer.
Cortellini A, D'Alessio A, Cleary S, Buti S, Bersanelli M, Bordi P, Tonini G, Vincenzi B, Tucci M, Russo A, Pantano F, Russano M, Stucci LS, Sergi MC, Falconi M, Zarzana MA, Santini D, Spagnolo F, Tanda ET, Rastelli F, Giorgi FC, Pergolesi F, Giusti R, Filetti M, Lo Bianco F, Marchetti P, Botticelli A, Gelibter A, Siringo M, Ferrari M, Marconcini R, Vitale MG, Nicolardi L, Chiari R, Ghidini M, Nigro O, Grossi F, De Tursi M, Di Marino P, Queirolo P, Bracarda S, Macrini S, Inno A, Zoratto F, Veltri E, Spoto C, Vitale MG, Cannita K, Gennari A, Morganstein DL, Mallardo D, Nibid L, Sabarese G, Brunetti L, Perrone G, Ascierto PA, Ficorella C, Pinato DJ. Cortellini A, et al. Among authors: marconcini r. Clin Cancer Res. 2023 Jul 14;29(14):2714-2724. doi: 10.1158/1078-0432.CCR-22-3116. Clin Cancer Res. 2023. PMID: 37125965
Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice.
Cortellini A, Tucci M, Adamo V, Stucci LS, Russo A, Tanda ET, Spagnolo F, Rastelli F, Bisonni R, Santini D, Russano M, Anesi C, Giusti R, Filetti M, Marchetti P, Botticelli A, Gelibter A, Occhipinti MA, Marconcini R, Vitale MG, Nicolardi L, Chiari R, Bareggi C, Nigro O, Tuzi A, De Tursi M, Petragnani N, Pala L, Bracarda S, Macrini S, Inno A, Zoratto F, Veltri E, Di Cocco B, Mallardo D, Vitale MG, Pinato DJ, Porzio G, Ficorella C, Ascierto PA. Cortellini A, et al. Among authors: marconcini r. J Immunother Cancer. 2020 Nov;8(2):e001361. doi: 10.1136/jitc-2020-001361. J Immunother Cancer. 2020. PMID: 33154150 Free PMC article.
Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma.
Baggi A, Quaglino P, Rubatto M, Depenni R, Guida M, Ascierto PA, Trojaniello C, Queirolo P, Saponara M, Peris K, Spagnolo F, Bianchi L, De Galitiis F, Potenza MC, Proietti I, Marconcini R, Botticelli A, Barbieri V, Licitra L, Alfieri S, Ficorella C, Cortellini A, Fargnoli MC, Troiani T, Tondulli L, Bossi P. Baggi A, et al. Among authors: marconcini r. Eur J Cancer. 2021 Nov;157:250-258. doi: 10.1016/j.ejca.2021.08.018. Epub 2021 Sep 15. Eur J Cancer. 2021. PMID: 34536948
The treatment of advanced melanoma: Current approaches and new challenges.
Boutros A, Croce E, Ferrari M, Gili R, Massaro G, Marconcini R, Arecco L, Tanda ET, Spagnolo F. Boutros A, et al. Among authors: marconcini r. Crit Rev Oncol Hematol. 2024 Apr;196:104276. doi: 10.1016/j.critrevonc.2024.104276. Epub 2024 Jan 29. Crit Rev Oncol Hematol. 2024. PMID: 38295889 Free article. Review.
Current status and perspectives in immunotherapy for metastatic melanoma.
Marconcini R, Spagnolo F, Stucci LS, Ribero S, Marra E, Rosa F, Picasso V, Di Guardo L, Cimminiello C, Cavalieri S, Orgiano L, Tanda E, Spano L, Falcone A, Queirolo P; Italian Melanoma Intergroup (IMI). Marconcini R, et al. Oncotarget. 2018 Jan 3;9(15):12452-12470. doi: 10.18632/oncotarget.23746. eCollection 2018 Feb 23. Oncotarget. 2018. PMID: 29552325 Free PMC article. Review.
Effect of Age on Melanoma Risk, Prognosis and Treatment Response.
Ribero S, Stucci LS, Marra E, Marconcini R, Spagnolo F, Orgiano L, Picasso V, Queirolo P, Palmieri G, Quaglino P, Bataille V. Ribero S, et al. Among authors: marconcini r. Acta Derm Venereol. 2018 Jul 11;98(7):624-629. doi: 10.2340/00015555-2944. Acta Derm Venereol. 2018. PMID: 29648671 Free article. Review.
Italian nivolumab Expanded Access Programme in melanoma adjuvant setting: patient outcomes and safety profile.
Ascierto PA, Di Giacomo AM, Chiarion Sileni V, Queirolo P, Spagnolo F, De Galitiis F, Cognetti F, Mandalà M, Guidoboni M, Rinaldi G, Depenni R, Consoli F, Troiani T, Guida M, Marconcini R, Ferrucci PF, Strippoli S, Fava P, Merelli B, Simeone E, Di Guardo L, Giannarelli D, Maio M, Quaglino P, Del Vecchio M. Ascierto PA, et al. Among authors: marconcini r. Eur J Cancer. 2023 Sep;191:113246. doi: 10.1016/j.ejca.2023.113246. Epub 2023 Jul 19. Eur J Cancer. 2023. PMID: 37549531
EZH2 Expression in Intestinal Neuroendocrine Tumors.
Faviana P, Marconcini R, Ricci S, Galli L, Lippolis P, Farci F, Castagna M, Boldrini L. Faviana P, et al. Among authors: marconcini r. Appl Immunohistochem Mol Morphol. 2019 Oct;27(9):689-693. doi: 10.1097/PAI.0000000000000647. Appl Immunohistochem Mol Morphol. 2019. PMID: 29489508
Vitamin D in melanoma: Controversies and potential role in combination with immune check-point inhibitors.
Stucci LS, D'Oronzo S, Tucci M, Macerollo A, Ribero S, Spagnolo F, Marra E, Picasso V, Orgiano L, Marconcini R, De Rosa F, Di Guardo L, Galli G, Gandini S, Palmirotta R, Palmieri G, Queirolo P, Silvestris F; Italian Melanoma Intergroup (IMI). Stucci LS, et al. Among authors: marconcini r. Cancer Treat Rev. 2018 Sep;69:21-28. doi: 10.1016/j.ctrv.2018.05.016. Epub 2018 May 31. Cancer Treat Rev. 2018. PMID: 29864718 Review.
48 results